|
US1051350A
(en)
|
1910-02-02 |
1913-01-21 |
Thomas Nogier |
Apparatus for the sterilization of liquids.
|
|
DE4124942A1
(de)
|
1991-07-27 |
1993-01-28 |
Thomae Gmbh Dr K |
5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
|
|
JPH08503971A
(ja)
|
1993-10-01 |
1996-04-30 |
チバ−ガイギー アクチェンゲゼルシャフト |
ピリミジンアミン誘導体及びその調製のための方法
|
|
TW440563B
(en)
|
1996-05-23 |
2001-06-16 |
Hoffmann La Roche |
Aryl pyrimidine derivatives and a pharmaceutical composition thereof
|
|
US6689778B2
(en)
|
2001-07-03 |
2004-02-10 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of Src and Lck protein kinases
|
|
US7396940B2
(en)
|
2003-10-23 |
2008-07-08 |
Hoffmann-La Roche Inc. |
Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
|
|
JP2008502687A
(ja)
|
2004-06-14 |
2008-01-31 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
|
EP1786813A2
(en)
|
2004-09-03 |
2007-05-23 |
Plexxikon, Inc. |
Bicyclic heteroaryl pde4b inhibitors
|
|
US7855205B2
(en)
|
2004-10-29 |
2010-12-21 |
Janssen Pharmaceutica Nv |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
|
GB0500492D0
(en)
|
2005-01-11 |
2005-02-16 |
Cyclacel Ltd |
Compound
|
|
WO2006096564A1
(en)
|
2005-03-04 |
2006-09-14 |
Merck & Co., Inc. |
Fused aromatic compounds having anti-diabetic activity
|
|
GB0520657D0
(en)
|
2005-10-11 |
2005-11-16 |
Ludwig Inst Cancer Res |
Pharmaceutical compounds
|
|
WO2007149427A2
(en)
|
2006-06-22 |
2007-12-27 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2008024978A2
(en)
|
2006-08-24 |
2008-02-28 |
Serenex, Inc. |
Tetrahydroindolone and tetrahydroindazolone derivatives
|
|
EP2155187B1
(en)
|
2007-05-07 |
2016-05-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
|
JP2010031249A
(ja)
|
2008-06-23 |
2010-02-12 |
Sumitomo Chemical Co Ltd |
組成物及び該組成物を用いてなる発光素子
|
|
NZ603525A
(en)
*
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
DE102008052943A1
(de)
*
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
|
CN101723936B
(zh)
|
2008-10-27 |
2014-01-15 |
上海睿星基因技术有限公司 |
激酶抑制剂及其在药学中的用途
|
|
EP2789614B1
(en)
|
2009-08-11 |
2017-04-26 |
Bristol-Myers Squibb Company |
Azaindazoles as Btk kinase modulators and use thereof
|
|
RU2595718C2
(ru)
|
2009-09-09 |
2016-08-27 |
Селджен Авиломикс Рисерч,Инк. |
Ингибиторы pi3-киназы и их применение
|
|
KR101116234B1
(ko)
|
2009-10-29 |
2014-03-06 |
(주)퓨쳐켐 |
(3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
|
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
|
ES2552462T3
(es)
|
2010-10-14 |
2015-11-30 |
Jw Pharmaceutical Corporation |
Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo
|
|
KR20130133051A
(ko)
|
2011-03-16 |
2013-12-05 |
에프. 호프만-라 로슈 아게 |
6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도
|
|
US20140303163A1
(en)
|
2011-03-24 |
2014-10-09 |
Ying Luo |
Use of kinase inhibitors in preventing and treating inflammatory disorder
|
|
MY161925A
(en)
*
|
2011-07-27 |
2017-05-15 |
Astrazeneca Ab |
2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
|
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
|
CN104379563B
(zh)
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
CN103508961B
(zh)
|
2012-06-26 |
2015-07-22 |
中美冠科生物技术（太仓）有限公司 |
抗肿瘤药物
|
|
WO2014047662A2
(en)
|
2012-09-24 |
2014-03-27 |
Whitehead Institute For Biomedical Research |
Indazole derivatives and uses thereof
|
|
US10112927B2
(en)
|
2012-10-18 |
2018-10-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
ES2831374T3
(es)
|
2012-11-21 |
2021-06-08 |
Janssen Biotech Inc |
Anticuerpos de EGFR/c-Met biespecíficos
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
HUE041881T2
(hu)
|
2013-04-29 |
2019-06-28 |
Chong Kun Dang Pharmaceutical Corp |
Új vegyületek mint szelektív hiszton dezacetiláz inhibitorok és az ezeket tartalmazó gyógyszerkészítmények
|
|
US20180057603A1
(en)
|
2013-08-09 |
2018-03-01 |
The Trustees Of The University Of Pennsylvania |
Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
|
|
KR102232595B1
(ko)
|
2013-08-30 |
2021-03-26 |
피티씨 테라퓨틱스, 인크. |
치환된 피리미딘 bmi-1 저해제
|
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
US20160319032A1
(en)
|
2013-10-01 |
2016-11-03 |
Medlmmune Limited |
Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
|
|
GB201400034D0
(en)
|
2014-01-02 |
2014-02-19 |
Astrazeneca Ab |
Pharmaceutical Compositions comprising AZD9291
|
|
CN104761544B
(zh)
|
2014-01-03 |
2019-03-15 |
北京轩义医药科技有限公司 |
Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
|
|
WO2015112705A2
(en)
|
2014-01-24 |
2015-07-30 |
Clovis Oncology, Inc. |
Therapeutic combinations for treating cancer
|
|
WO2015127234A1
(en)
|
2014-02-20 |
2015-08-27 |
Board Of Regents, The University Of Texas System |
Use of ibrutinib to treat egfr mutant cancer
|
|
CN104860941B
(zh)
*
|
2014-02-25 |
2017-03-22 |
上海海雁医药科技有限公司 |
2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
|
|
CN104876914B
(zh)
|
2014-02-28 |
2017-04-19 |
山东轩竹医药科技有限公司 |
嘧啶衍生物类间变性淋巴瘤激酶抑制剂
|
|
TW201622744A
(zh)
|
2014-03-04 |
2016-07-01 |
美國禮來大藥廠 |
癌症之組合療法
|
|
CN108558842B
(zh)
|
2014-03-06 |
2021-06-04 |
山东轩竹医药科技有限公司 |
嘧啶衍生物类间变性淋巴瘤激酶抑制剂
|
|
RU2016141934A
(ru)
|
2014-04-04 |
2018-05-07 |
Сирос Фармасьютикалз, Инк. |
Ингибиторы циклин-зависимой киназы 7 (cdk7)
|
|
AU2015242407B2
(en)
|
2014-04-04 |
2017-11-09 |
Astrazeneca Ab |
Combination of EGFR inhibitor and MEK inhibitor for use in the treatment of NRAS mutated cancer
|
|
WO2015175965A1
(en)
|
2014-05-15 |
2015-11-19 |
The Research Foundation For Suny |
Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
|
|
CN106660993B
(zh)
|
2014-06-12 |
2020-09-11 |
上海复尚慧创医药研究有限公司 |
一类激酶抑制剂
|
|
MY186839A
(en)
*
|
2014-06-19 |
2021-08-25 |
Takeda Pharmaceuticals Co |
Heteroaryl compounds for kinase inhibition
|
|
EP3169706B1
(en)
|
2014-07-11 |
2019-12-04 |
Genmab A/S |
Antibodies binding axl
|
|
CN105254615B
(zh)
|
2014-07-11 |
2017-02-22 |
杭州华东医药集团新药研究院有限公司 |
苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
|
|
CN105315285B
(zh)
|
2014-07-25 |
2017-12-08 |
上海海雁医药科技有限公司 |
2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
|
|
EP3180344B1
(en)
*
|
2014-08-12 |
2019-09-18 |
Pfizer Inc |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
CN104140418B
(zh)
|
2014-08-15 |
2016-08-24 |
常州润诺生物科技有限公司 |
2-(2，4，5-取代苯胺)嘧啶衍生物及其用途
|
|
EP3180029A1
(en)
|
2014-08-15 |
2017-06-21 |
Boehringer Ingelheim International GmbH |
Afatinib pharmaceutical kit for cancer treatment
|
|
WO2016029839A1
(zh)
|
2014-08-25 |
2016-03-03 |
四川海思科制药有限公司 |
一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途
|
|
WO2016032003A1
(ja)
|
2014-08-30 |
2016-03-03 |
国立大学法人金沢大学 |
肺癌患者用治療剤及び肺癌患者治療の有効性の予測検査方法
|
|
WO2016038610A1
(en)
|
2014-09-08 |
2016-03-17 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
|
|
WO2016038609A1
(en)
|
2014-09-08 |
2016-03-17 |
Yeda Research And Development Co. Ltd. |
Anti-her3 antibodies and uses of same
|
|
WO2016040622A1
(en)
|
2014-09-11 |
2016-03-17 |
Bulldog Pharmaceuticals, Inc. |
Uses of anti-her3 antibodies for treating cancer
|
|
ES2843829T3
(es)
|
2014-09-26 |
2021-07-20 |
Hi Stem Ggmbh Im Deutschen Krebsforschungszentrum Dkfz |
Nuevos métodos para la subtipificación y el tratamiento del cáncer
|
|
CN105461695B
(zh)
|
2014-09-29 |
2018-03-27 |
齐鲁制药有限公司 |
嘧啶或三嗪衍生物及其制备方法和用途
|
|
CN105237515B
(zh)
|
2014-10-10 |
2018-06-05 |
益方生物科技（上海）有限公司 |
氘代嘧啶类化合物、其制备方法、药物组合物和用途
|
|
PL3205650T3
(pl)
|
2014-10-11 |
2021-12-06 |
Shanghai Hansoh Biomedical Co., Ltd. |
Inhibitor EGFR i jego otrzymywanie i zastosowanie
|
|
NZ730012A
(en)
*
|
2014-10-13 |
2019-06-28 |
Yuhan Corp |
Compounds and compositions for modulating egfr mutant kinase activities
|
|
US10308648B2
(en)
|
2014-10-16 |
2019-06-04 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
|
CN105085489B
(zh)
|
2014-11-05 |
2019-03-01 |
益方生物科技（上海）有限公司 |
嘧啶或吡啶类化合物、其制备方法和医药用途
|
|
EP3226869A4
(en)
|
2014-12-03 |
2018-07-18 |
Auckland UniServices, Ltd. |
Kinase inhibitor prodrug for the treatment of cancer
|
|
SG11201704685TA
(en)
|
2014-12-11 |
2017-07-28 |
Beta Pharma Inc |
Substituted 2-anilinopyrimidine derivatives as egfr modulators
|
|
FI3236943T3
(fi)
|
2014-12-24 |
2023-04-27 |
Principia Biopharma Inc |
Koostumuksia ileo-jejunaaliseen lääkkeenantoon
|
|
WO2016112302A1
(en)
|
2015-01-09 |
2016-07-14 |
Metastat, Inc. |
Method of predicting sensitivity of tumor cell growth to combination therapy of fgfr inhibitor
|
|
WO2016112272A1
(en)
|
2015-01-09 |
2016-07-14 |
Metastat, Inc. |
Method of use for inhibitors of epidermal growth factor receptor variant iii
|
|
SG11201705952SA
(en)
|
2015-02-04 |
2017-09-28 |
Beyondbio Inc |
Heterocyclic compound and pharmaceutical composition comprising same
|
|
JP2018504418A
(ja)
|
2015-02-05 |
2018-02-15 |
ティルノーヴォ リミテッド |
癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ
|
|
CN104961731A
(zh)
|
2015-02-05 |
2015-10-07 |
苏州晶云药物科技有限公司 |
一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
|
|
CN105985323A
(zh)
|
2015-02-15 |
2016-10-05 |
宁波文达医药科技有限公司 |
新型表皮生长因子受体抑制剂及其应用
|
|
WO2016141324A2
(en)
|
2015-03-05 |
2016-09-09 |
Trovagene, Inc. |
Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids
|
|
CN106138020A
(zh)
|
2015-04-03 |
2016-11-23 |
中国人民解放军第三军医大学第三附属医院 |
双胍类药物在制备预防或减弱肺纤维化的药物中的应用
|
|
CN106138061B
(zh)
|
2015-04-03 |
2019-06-04 |
中国人民解放军第三军医大学第三附属医院 |
预防或减弱肺纤维化的复合物及其制剂和用途
|
|
WO2016164217A1
(en)
|
2015-04-09 |
2016-10-13 |
Clovis Oncology, Inc. |
Therapeutic combinations for treating cancer
|
|
CN104844580B
(zh)
|
2015-04-17 |
2017-10-20 |
中国药科大学 |
嘧啶类化合物、其制备方法及医药用途
|
|
RU2017136709A
(ru)
|
2015-04-23 |
2019-05-23 |
Медиммьюн Лимитед |
Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr
|
|
CN104817541B
(zh)
|
2015-05-11 |
2017-06-16 |
苏州东南药业股份有限公司 |
一种抗肿瘤药物的合成方法
|
|
CN108012529A
(zh)
|
2015-05-15 |
2018-05-08 |
诺华股份有限公司 |
治疗egfr突变的癌症的方法
|
|
PT3297438T
(pt)
|
2015-05-21 |
2022-01-25 |
Chemocentryx Inc |
Moduladores de ccr2
|
|
US20180117053A1
(en)
|
2015-05-27 |
2018-05-03 |
Metastat, Inc. |
The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI
|
|
AU2016270375B2
(en)
|
2015-06-03 |
2021-05-13 |
Chang Gung Medical Foundation Keelung Chang Gung Memorial Hospital |
Methods and compositions for treating non-small cell lung cancer
|
|
US20160355503A1
(en)
|
2015-06-04 |
2016-12-08 |
Cleave Biosciences, Inc. |
NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX
|
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
|
|
CN104910049B
(zh)
|
2015-06-16 |
2016-06-29 |
苏州明锐医药科技有限公司 |
Azd9291中间体及其制备方法
|
|
CA2991805A1
(en)
|
2015-07-10 |
2017-01-19 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
|
PL3325662T3
(pl)
|
2015-07-17 |
2024-02-26 |
Pacylex Pharmaceuticals Inc. |
Wyciszenie epigenetyczne nmt2
|
|
EP3325469A4
(en)
|
2015-07-20 |
2019-01-23 |
Dana Farber Cancer Institute, Inc. |
NOVEL PYRIMIDINS AS EGFR INHIBITORS AND METHOD FOR THE DISEASE TREATMENT THEREWITH
|
|
TW201716439A
(zh)
|
2015-07-20 |
2017-05-16 |
美國禮來大藥廠 |
Ｈｅｒ３抗體
|
|
EP3120851A1
(en)
|
2015-07-21 |
2017-01-25 |
Pangaea Biotech S.L. |
4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
|
|
WO2017016463A1
(zh)
|
2015-07-24 |
2017-02-02 |
上海海雁医药科技有限公司 |
Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
|
|
CN105001208A
(zh)
|
2015-08-06 |
2015-10-28 |
南京雷科星生物技术有限公司 |
一种表皮生长因子受体egfr抑制剂及其制备方法与用途
|
|
US10980765B2
(en)
|
2015-08-14 |
2021-04-20 |
Board Of Supervisors Of Louisiana State University |
Isothiocyanatostilbenes as a novel method and product for treating cancer
|
|
CN105153122B
(zh)
|
2015-08-27 |
2018-07-20 |
上海圣考医药科技有限公司 |
[(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
|
|
CN110483485A
(zh)
|
2015-09-02 |
2019-11-22 |
益方生物科技（上海）有限公司 |
嘧啶类化合物、其制备方法和医药用途
|
|
CN105126125A
(zh)
|
2015-09-12 |
2015-12-09 |
复旦大学 |
一种氧化锌-钆-药物复合纳米粒子及其制备方法和应用
|
|
JP6767491B2
(ja)
|
2015-09-25 |
2020-10-14 |
ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド |
Ｊａｋを阻害するための化合物及び方法
|
|
AU2016343517B2
(en)
|
2015-10-19 |
2020-04-30 |
Sunshine Lake Pharma Co., Ltd. |
A salt of EGFR inhibitor, crystalline form and uses thereof
|
|
US20170115275A1
(en)
|
2015-10-23 |
2017-04-27 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
|
|
US10093668B2
(en)
|
2015-10-28 |
2018-10-09 |
Northwestern University |
Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)
|
|
AU2016349781A1
(en)
|
2015-11-02 |
2018-05-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
|
CN106674202A
(zh)
|
2015-11-05 |
2017-05-17 |
惠州信立泰药业有限公司 |
化合物a的二甲磺酸盐及其晶型和含有该盐的药物组合物
|
|
CN106699736A
(zh)
|
2015-11-17 |
2017-05-24 |
惠州信立泰药业有限公司 |
化合物A甲磺酸盐的晶型γ和含有该晶型的药物组合物
|
|
CN105461729B
(zh)
|
2015-11-18 |
2017-12-05 |
乳源瑶族自治县大众药品贸易有限公司 |
一种egfr抑制剂的盐、晶型及其用途
|
|
CN105294717B
(zh)
|
2015-11-18 |
2017-12-22 |
乳源瑶族自治县大众药品贸易有限公司 |
一种egfr抑制剂的盐、晶型及其用途
|
|
RU2606949C9
(ru)
|
2015-11-19 |
2018-03-14 |
ЗАО "Р-Фарм" |
Замещенные N-{ 3-[4-(1-метил-1Н-индол-3-ил)пиримидин-2-иламино]-4-метоксифенил} -амиды в качестве модуляторов EGFR, предназначенные для лечения рака
|
|
RU2603960C1
(ru)
|
2015-11-19 |
2016-12-10 |
Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") |
Дихлорацетат n1,n2-дизамещенного n4-[4-(1-метил-1н-индол-3-ил)-пиримидин-2-ил]-5-метоксибензол-1,2,4-триамина в качестве модулятора egfr для лечения рака
|
|
CN105348267A
(zh)
|
2015-12-01 |
2016-02-24 |
中山奕安泰医药科技有限公司 |
合成azd9291中间体的方法
|
|
EP3383877B1
(en)
|
2015-12-03 |
2021-09-15 |
Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. |
Heterocycle compounds and uses thereof
|
|
US10829495B2
(en)
|
2015-12-03 |
2020-11-10 |
Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. |
Thieno-pyrimidine derivatives and uses thereof
|
|
CN108602890A
(zh)
|
2015-12-11 |
2018-09-28 |
瑞泽恩制药公司 |
用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
|
|
TWI623316B
(zh)
|
2015-12-22 |
2018-05-11 |
Taiho Pharmaceutical Co Ltd |
Antitumor effect enhancer derived from pyrrolopyrimidine compound
|
|
CN105601620A
(zh)
|
2015-12-25 |
2016-05-25 |
北京康立生医药技术开发有限公司 |
一种甲磺酸迈瑞替尼的制备方法
|
|
KR102029135B1
(ko)
|
2015-12-27 |
2019-10-07 |
뉴폼 파마슈티컬스, 아이엔씨. |
암 및 관련 질병 및 상태 치료용 중수소화된 화합물, 그의 조성물 및 방법
|
|
CN106928150B
(zh)
|
2015-12-31 |
2020-07-31 |
恩瑞生物医药科技（上海）有限公司 |
丙烯酰胺苯胺衍生物及其药学上的应用
|
|
TWI726968B
(zh)
|
2016-01-07 |
2021-05-11 |
開曼群島商Ｃｓ醫藥技術公司 |
Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
|
|
MX388579B
(es)
|
2016-01-08 |
2025-03-20 |
Euclises Pharmaceuticals Inc |
Combinacion de un compuesto de cromeno y un segundo agente activo.
|
|
CA3010711A1
(en)
|
2016-01-08 |
2017-07-13 |
The Regents Of The University Of California |
Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
|
|
CN105646454B
(zh)
|
2016-01-19 |
2018-05-08 |
浙江大学 |
含异羟肟酸片段的2-芳胺基嘧啶类衍生物及制备和应用
|
|
TWI745345B
(zh)
|
2016-02-01 |
2021-11-11 |
瑞典商阿斯特捷利康公司 |
製備奧希替尼（osimertinib，azd9291）或其鹽及「azd9291苯胺」或其鹽的改良方法
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
SG11201805375PA
(en)
|
2016-02-04 |
2018-07-30 |
Stem Cell Theranostics Inc |
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
|
|
CN108601781B
(zh)
|
2016-02-04 |
2019-11-22 |
广州必贝特医药技术有限公司 |
作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
|
|
CN105777716B
(zh)
|
2016-02-25 |
2018-04-10 |
清华大学 |
一种用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
|
|
CN105585557B
(zh)
|
2016-02-25 |
2018-06-22 |
清华大学 |
用于靶向治疗癌症的egfr抑制剂及其制备方法与应用
|
|
AU2017269335B2
(en)
|
2016-05-26 |
2021-07-01 |
Recurium Ip Holdings, Llc |
EGFR inhibitor compounds
|
|
CN105886648A
(zh)
|
2016-06-06 |
2016-08-24 |
武汉海吉力生物科技有限公司 |
用于检测egfr基因t790m突变的试剂盒
|
|
CN106366022B
(zh)
|
2016-08-19 |
2018-03-13 |
上海工程技术大学 |
一种用于制备azd9291的中间体及其制备方法和应用
|
|
CN106366072B
(zh)
|
2016-08-19 |
2018-12-07 |
上海工程技术大学 |
一种azd9291的制备方法
|
|
CN106397407B
(zh)
|
2016-08-31 |
2018-09-04 |
浙江科聚化工有限公司 |
抗肿瘤药物azd9291衍生物的制备方法
|
|
CN106432231B
(zh)
|
2016-09-09 |
2018-06-12 |
无锡佰翱得生物科学有限公司 |
Azd9291的药用盐、及其晶型和制备方法
|
|
CN106565522A
(zh)
|
2016-09-29 |
2017-04-19 |
福格森（武汉）生物科技股份有限公司 |
一种由氟代芳香化合物制备烷氧基芳香化合物的方法
|
|
CN106496196B
(zh)
|
2016-10-20 |
2019-07-02 |
南京雷科星生物技术有限公司 |
一种喹唑啉、吡啶并嘧啶或则双并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
|
|
CN106543060B
(zh)
|
2016-10-31 |
2018-11-06 |
湖南欧亚药业有限公司 |
一种奥斯替尼甲磺酸盐的制备方法
|
|
CN106668866A
(zh)
|
2017-02-13 |
2017-05-17 |
江苏省中医药研究院 |
一种抗非小细胞肺癌的药物组合物及其应用
|
|
CN106883216B
(zh)
|
2017-04-06 |
2020-03-13 |
张家港威胜生物医药有限公司 |
一种奥希替尼的制备方法
|